Thermo Fisher Scientific Announces Pricing of Euro-Denominated Senior Notes Offering

WALTHAM, Mass. – Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in scientific instrumentation and services, has announced the pricing of a €2.1 billion euro-denominated notes offering. The notes, to be issued by its indirect, wholly-owned finance subsidiary, Thermo Fisher Scientific (Finance I) B.V., will consist of:

• €1,000,000,000 in floating rate senior notes due 2027, priced at 100.000% of their principal amount.
• €1,100,000,000 in 3.628% fixed rate senior notes due 2035, priced at 100.000% of their principal amount.

The offering, anticipated to close around December 1, 2025, is contingent upon customary closing conditions. Thermo Fisher will fully and unconditionally guarantee the notes. Interest on the floating rate notes will be paid quarterly, while the fixed-rate notes will bear annual interest payments.

The move comes as Thermo Fisher seeks to optimize its capital structure and pursue strategic growth initiatives. The company stated its intention to use the net proceeds for general corporate purposes. These include, but are not limited to, potential acquisitions, debt repayment and refinancing, working capital investments, capital expenditures, or share repurchases. The flexibility to deploy capital strategically is crucial in the current macroeconomic environment. Alternatively, funds could be temporarily invested in short-term, liquid assets.

Barclays Bank PLC, BNP PARIBAS, HSBC Continental Europe, and Morgan Stanley & Co. International plc are acting as joint book-running managers for the offering.

This offering is being made under an effective registration statement on Form S-3ASR (File No. 333-285159) previously filed with the U.S. Securities and Exchange Commission (SEC). Interested parties are encouraged to consult the prospectus supplement and accompanying prospectus filed with the SEC for comprehensive details regarding Thermo Fisher and this offering. These documents are accessible without charge via the SEC’s EDGAR database at www.sec.gov.

The company’s decision to tap the Eurobond market reflects a strategic assessment of prevailing interest rate conditions and investor demand in Europe. It could allow Thermo Fisher to diversify its funding sources and potentially achieve more favorable borrowing costs compared to other markets. Bond yields, particularly in the Eurozone, have been closely watched by corporations seeking long-term financing, and this offering suggests Thermo Fisher sees an opportunity to lock in attractive rates.

It’s important to note that this press release is not an offer to sell, nor a solicitation of an offer to buy these notes. Any such offer, solicitation, or sale would be unlawful in jurisdictions lacking prior registration or qualification under applicable securities laws.

MiFID II and UK MiFIR – professionals/ECPs-only / No PRIIPs or UK PRIIPs KID – Manufacturer target market (MiFID II and UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs or UK PRIIPs key information document (KID) has been prepared as not available to retail in the European Economic Area or United Kingdom.

The communication of this pricing press release, the prospectus supplement, the accompanying prospectus, any related free writing prospectus and any other document or materials relating to the issue of the notes described herein is not being made, and this pricing press release, the prospectus supplement, the accompanying prospectus, any related free writing prospectus and such other documents and/or materials have not been approved, by an authorized person for the purposes of section 21 of the United Kingdom’s Financial Services and Markets Act 2000, as amended. Accordingly, this pricing press release, the prospectus supplement, the accompanying prospectus, any related free writing prospectus and such other documents and/or materials are not being distributed to, and must not be passed on to, the general public in the United Kingdom. This pricing press release, the prospectus supplement, the accompanying prospectus, any related free writing prospectus and such other documents and/or materials are for distribution only to persons who (i) have professional experience in matters relating to investments and who fall within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Financial Promotion Order”)), (ii) fall within Article 49(2)(a) to (d) of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are any other persons to whom it may otherwise lawfully be communicated or distributed under the Financial Promotion Order (all such persons together being referred to as “relevant persons”). This pricing press release, the prospectus supplement, the accompanying prospectus, any related free writing prospectus and any such other document and/or materials are directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this pricing press release, the prospectus supplement, the accompanying prospectus, any related free writing prospectus and any such other documents and/or materials relate will be engaged in only with relevant persons. Any person in the United Kingdom that is not a relevant person should not act or rely on this pricing press release, the prospectus supplement, the accompanying prospectus or any related free writing prospectus or any other documents and/or materials relating to the issue of the notes described herein or any of their contents.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about timing and completion of the Offering and Thermo Fisher’s intended use of proceeds therefrom. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including risks and uncertainties relating to capital markets conditions and completion of the Offering. Additional important factors and information regarding Thermo Fisher’s business that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” section of the prospectus dated February 24, 2025 and the preliminary prospectus supplement dated November 24, 2025 related to the Offering and the other documents incorporated by reference into the prospectus and prospectus supplement, which are on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings.” These forward-looking statements are based on our current expectations and speak only as of the date of this press release. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, in the event of new information, future developments or otherwise.